Vivacelle Bio, Inc.

Vivacelle Bio is a late-stage biopharma company based in Kansas City, Missouri, developing life-saving treatments for shock and trauma. Leveraging our pioneering and patented phospholipid nanoparticle technology, we address the urgent global crisis of sepsis and acute hemorrhage.

Millions of lives are lost each year due to sepsis, a leading cause of death worldwide, often stemming from relative or absolute hypovolemia. Our lead product, VBI-S, utilizes a unique mechanism to redistribute nitric oxide, elevating blood pressure in patients who are refractory to standard fluid therapy.

This innovative approach represents a new paradigm in critical care, offering a potential lifeline for patients facing devastating outcomes. We’ve secured backing from venture capital, the US Department of Defense, and the National Institutes of Health, and are currently enrolling patients in a Phase III clinical trial. VBI-S aims to transform treatment outcomes and save countless lives.

We are committed to advancing this technology and bringing a much-needed solution to patients and healthcare providers worldwide.